Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DPYD | Q12882 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532356 | 1.00 | LMNA (0.53) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL2532358 | 1.00 | LMNA (0.53) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL1165152 | 0.74 | LMNA (0.48) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL20534511 | 0.73 | LMNA (0.62) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL2552963 | 0.72 | CYP3A4 (0.57) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL23055551 | 0.71 | LMNA (0.69) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL31258082 | 0.70 | ALDH1A1 (0.62) | LMNAALDH1A1CYP1A2SMN1; SMN2POLB | |
| SCHEMBL31045621 | 0.70 | LMNA (0.54) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL31510364 | 0.68 | LMNA (0.56) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 | |
| SCHEMBL1165153 | 0.68 | ALDH1A1 (0.49) | LMNAALDH1A1CYP1A2SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-8609666-B2 | 2-morpholino-pyrido[3,2-D]pyrimidines | MERCK SERONO SA (CH) | 2013-12-17 | — | — | US | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| EP-1786812-B1 | PYRIDINE METHYLENE AZOLIDINONES AND THEIR USE AS PHOSPHOINOSITIDE INHIBITORS | MERCK SERONO SA (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-7842698-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| EP-1786812-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024666-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | PIK3CD, PIK3CA, PIK3CB | LMNA 4503/4885ALDH1A1 1437/4885CYP1A2 2519/4885 |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CB | LMNA 2893/4885ALDH1A1 4135/4885CYP1A2 2809/4885 |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | LMNA 4183/4885ALDH1A1 2503/4885CYP1A2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.